Sensorion SA (FRA:RFM)

Market Cap	183.24M +10.9%
Revenue (ttm)	5.81M -12.6%
Net Income	-29.43M
EPS	-0.10
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	500
Open	0.3790
Previous Close	0.3780
Day's Range	0.3350 - 0.3790
52-Week Range	0.1210 - 0.6500
Beta	n/a
RSI	42.66
Earnings Date	Mar 30, 2026

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ...

• Industry: Pharmaceutical Preparations
• Founded: 2009
• Employees: 68
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: RFM

Financial Performance

In 2025, Sensorion's revenue was 5.81 million, a decrease of -12.61% compared to the previous year's 6.65 million. Losses were -29.43 million, 13.3% more than in 2024.